If you need more information about the Xarelto litigation, contact David Byrne at 800-898-2034 or by email at David.Byrne@beasleyallen.com. Read more
It appears that drug manufacturers may have been submitting incomplete reports of side-affects to the FDA for a very long time. Read more
Xarelto has generated nearly $2 billion in revenue since it was approved in 2011. Read more
Johnson & Johnson was once a well-respected company in this country and in many circles it still is. But based on our firm’s litigation experience with this company, I am convinced that... Read more
Sonny Wills, who has been with the firm for one year, is a lawyer in the firm’s Mass Torts Section. Read more
Activity in our firm’s Mass Torts Section is at a record pace. Lawyers in the Section have been very busy on several fronts. They will investigate any potential claim involving a medication... Read more
Lawsuits filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Corp. over the blood thinner Xarelto have been consolidated in Louisiana federal court. Xarelto has... Read more
Lawyers in our firm are continuously being asked about what all our Mass Torts Section is doing. So we will again give an update on activity in the section. Lawyers in the Section will inves... Read more
Andy D. Birchfield, who heads up our firm’s Mass Torts Section, has been named Co-Lead Counsel for the Plaintiffs Steering Committee (PSC) in the multidistrict litigation (MDL) involving the... Read more
The U.S. Food and Drug Administration has recommended against the immediate approval of Xarelto, which is Bayer AG and Johnson & Johnson’s anti-clotting drug, as a treatment to prevent... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.